Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Mallinckrodt to co-promote Zogenix’s Sumavel DosePro in the US; terminated

Executive Summary

Less than two months after ending its agreement with Astellas Pharma US, pain management company Zogenix Inc. has licensed Mallinckrodt LLC, the pharmaceutical division of Covidien PLC’s Covidien Ltd., exclusive US co-promotion rights to its marketed product Sumavel DosePro (sumatriptan injection) for acute migraine or cluster headache. The deal expires on June 30, 2014, but may be extended by six-month increments.
Deal Industry
  • Medical Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • Marketing (Licensing)

Related Companies